HELIOS-B trial – Vutrisiran Reduces Risk of Outpatient Worsening Heart Failure in ATTR-CM in a subgroup analysis
Key Points: Transthyretin amyloidosis (ATTR-CM) is a fatal disease caused by the deposition of misfolded amyloid protein in the heart, leading to heart failure and poor cardiovascular outcomes. In the…
ARREST-AF: Aggressive Risk Factor Management After AF Ablation Reduces Arrythmia Recurrence at 12 Months
Key Points Observation data has suggested that improving cardiometabolic risk factors after AF ablation may reduce the recurrence of arrythmias. The ARREST-AF trial provides randomized controlled evidence demonstrating the benefits…
SUMMIT CMR: Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related HFpEF
Key Points Obesity-related heart failure with preserved ejection fraction (HFpEF) is associated with increased left ventricular (LV) concentric remodeling and paracardiac adipose tissue (PAT), which may exacerbate HFpEF through systemic…
SCAN-MP Study: High Prevalence of Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals with Heart Failure
Key Points ATTR cardiac amyloidosis (ATTR-CA) is frequently diagnosed in older Black individuals with heart failure (HF), particularly in men over 75 years of age. The SCAN-MP study provides observational…
LAA Closure Associated With Less Bleeds vs. Oral Anticoagulation Post AF Ablation: OPTION
Key Takeaways: The OPTION TRIAL assessed the safety and efficacy of WATCHMAN FLX in a post-ablation contemporary clinical AF patient population at risk of stroke. The trial showed that left…
Optimization of GDMT Very Modest but Increased Use of MRAs with Audit and Feedback: PHARM-HF A&F Study
Key Points: Over 6 million people in the US live with heart failure (HF), but national rates of GDMT treatment remain low Because pharmacists can prescribe medication and often manage…
A SUMMIT Analysis: Tirzepatide Reduces End Organ Damage in Patients with Obesity and HFpEF
Key Points SUMMIT, a randomized control trial of tirzepatide versus placebo in patients with HFpEF and obesity, found that tirzepatide significantly reduced the risk of worsening heart failure events and…
NUDGE-FLU Pool Analysis: Email Reminders Highlighting CV Benefits of Flu Shots Effective for Increasing Vaccine Uptake Post-MI
Key Points Three prior randomized trials including over two million adults in Denmark demonstrated that a variety of electronic message reminders, or “nudges”, to receive the influenza vaccination led to…
Edoxaban Comparable to Warfarin After Surgical Bioprosthetic Valves Implantation: ENBALV Trial
Key Points: In patients after surgical bioprosthetic valves, it remains unclear if edoxaban is safe and effective in preventing valve complicates early after surgery. In this randomized clinical trial, 389…
PanEcho: AI-Based Automated Image Analysis Improved Quality and Efficiency in Echocardiography
Key Points: Transthoracic echocardiography is foundational to diagnosis and evaluation of myriad conditions, but image interpretation and results reporting depends on manual reporting As opposed to previous applications of artificial…
TOPSPIN- A: Three-Combination of Antihypertensive Meds Provided Similar BP Control
Key Points: The global burden of hypertension (HTN) with high globally at 1.3 billion people and locally in India with 300 million affected Despite making up 25% of the global…
Personalized App-Based Coaching Improved Physical Activity in HFpEF Patients (MyoMobile Study)
Key Points: Though physical inactivity leads to poor cardiovascular outcomes, especially for those with cardiovascular disease, few studies have been performed to validate the utility of effective lifestyle interventions in…
ZODIAC: A Risk-based Decision Support System Did Not Significantly Improve Lipid-Lowering vs Usual Care
Key Points Maximizing lipid lowering therapy (LLTs) to optimize residual cardiovascular disease (CVD) risk after acute coronary syndrome (ACS) is usually a stepwise approach that can take months or years…
Exenatide, a GLP-1 Analog, Did Not Reduce Organ Injury, Stroke or Death During Cardiac Surgery: GLORIOUS Trial
KEY POINTS: Exenatide is a glucaon-like-peptide-1 agonist (GLP-1) improves glycemic control, and other medications in this class, appear to reduce the risk of cardiovascular disease The GLORIOUS Trial evaluated intravenous…
Plozasiran Showed Sustained Reductions in TG in Familial Chylomicronemia Syndrome: PALISADE Trial
Key Points: Familial chylomicronemia syndrome (FCS) is characterized by extremely high plasma triglycerides (TGs) due to failure of clearance of chylomicrons, of which the most severe sequela is acute pancreatitis…
Catheter Ablation Better Than Antiarrhythmic Drugs for VT in Ischemic Cardiomyopathy With ICD: VANISH2 Trial
Key Takeaways: The VANISH2 trial compared catheter ablation with systematic antiarrhythmic drug therapy as a first-line treatment strategy in patients with an ICD ischemic cardiomyopathy, and ventricular tachycardia who had…
CLEAR SYNERGY: No Benefit with Routine Spironolactone in MI Patients
Key Takeaways: The CLEAR SYNERGY trial was a multicenter trial with a 2-by-2 factorial design which randomly assigned patients with myocardial infarction who had undergone percutaneous coronary intervention to receive…
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran Associated with Durable Reductions in Serum TTR levels for ATTR -CM
Key Takeaways: A single dose of nexiguran ziclumeran (nex-z), a CRISPR-Cas9-based therapy, achieved a 90% reduction in serum transthyretin (TTR) levels at 12 months (95% CI, −93 to −87). NT-proBNP levels showed…
SUMMIT: Tirzepatide Decreased The Risk Of Worsening HF And CV Death in HFpEF + Obesity
Key Points SUMMIT was a multi-national trial that compared cardiovascular outcomes among patients with heart failure with preserved ejection fraction (HFpEF) and obesity that were randomized to tirzepatide (a GLP-1…
BPROAD: Intensive Blood Pressure Target Reduces MACE in Type 2 Diabetes
Key Points BPROAD was a randomized control trial in China that assigned nearly 13,000 participants with type 2 diabetes (T2DM) and hypertension (HTN) to either a systolic blood pressure target…